106973-36-8

Basic information

• Product Name: (R)-4-Benzyl-5-oxo-3-morpholinecarboxylic Acid
• Synonyms: (R)-4-Benzyl-5-oxo-3-morpholinecarboxylic Acid;(S)-5-oxo-4-(phenylMethyl)Morpholine-3-carboxylicacid;(3R)-5-oxo-4-(phenylmethyl)-3-Morpholinecarboxylic acid;(3R)-4-Benzyl-5-oxomorpholine-3-carboxylic acid
• CAS NO: 106973-36-8
• Molecular Formula: C₁₂H₁₃NO₄
• Molecular Weight: 235.23592
• Mol File: 106973-36-8.mol
• Article Data: 13

Chemical Properties

• Melting Point: 177-178 °C(Solv: isopropanol (67-63-0))
• Boiling Point: 506.835°C at 760 mmHg
• Flash Point: 260.325°C
• Appearance: /
• Density: 1.34g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.22±0.20(Predicted)
• CAS DataBase Reference: (R)-4-Benzyl-5-oxo-3-morpholinecarboxylic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-Benzyl-5-oxo-3-morpholinecarboxylic Acid(106973-36-8)
• EPA Substance Registry System: (R)-4-Benzyl-5-oxo-3-morpholinecarboxylic Acid(106973-36-8)

Safety Data

• Hazardous Substances Data: 106973-36-8(Hazardous Substances Data)

Usage

Uses

(R)-4-Benzyl-5-oxo-3-morpholinecarboxylic Acid is a Morpholine (M723725) based compound that can be synthesized from Serine enantiomers and reduction of 5-oxomorpholine-3-carboxylates as key step.

InChI:InChI=1/C12H13NO4/c14-11-8-17-7-10(12(15)16)13(11)6-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,15,16)/t10-/m1/s1

Upstream product

• 1007169-00-7 (R)-2-(N-benzyl-2-chloroacetamido)-3-hydroxypropanoic acid 
• 106910-77-4 N-(phenylmethyl)-D-serine 
• 79-04-9 chloroacetyl chloride 
• 515156-88-4 N-benzyl-D-serine 
• 100-52-7 benzaldehyde 

Downstream Products

• 106910-85-4 ethyl (R)-4-benzylmorpholine-3-carboxylate 
• 1152110-17-2 1-phenyl-N-{[(3S)-4-(phenylmethyl)-3-morpholinyl]methyl}methanamine 
• 1089280-12-5 ethyl oxo((phenylmethyl){[(3S)-4-(phenylmethyl)-3-morpholinyl]methyl}amino)acetate 
• 1089280-11-4 (9aS)-8-(phenylmethyl)hexahydropyrazino[2,1-c][1,4]oxazine-6,7-dione 
• 1089280-13-6 (9aS)-8-(phenylmethyl)octahydropyrazino[2,1-c][1,4]oxazine 
• 1126432-04-9 (9aS)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride 
• 1152110-20-7 [(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methyl-4-pyrimidinyl}hydrazino)-3-oxopropyl][(phenylmethyl)oxy]formamide 
• 1152107-25-9 GSK1322322 
• 211053-50-8 (S)-3-(hydroxymethyl)morpholine 
• 1268364-50-6 (S)-1-benzyloxymethyl-2-((R)-3-chloromethyl-morpholin-4-yl)ethylamine 
• 1268364-49-3 [(S)-1-benzyloxymethyl-2-((R)-3-chloromethyl-morpholin-4-yl)-ethyl] carbamic acid tert-butyl ester 
• 1268364-48-2 [(S)-1-benzyloxymethyl-2-((S)-3-hydroxymethyl-morpholin-4-yl)-ethyl] carbamic acid tert-butyl ester 
• 1268364-45-9 (7S,9aS)-7-[(benzyloxy)methyl]octahydropyrazino[2,1-c][1,4]oxazine 
• 916483-67-5 [(3S)-4-benzylmorpholin-3-yl]methanol hydrochloride 

Relevant articles and documents

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

ANHYDRATE FORMS OF A PYRIDINE DERIVATIVE

The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention is directed to certain {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I), wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.